Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.52 |
| ▸ | CD44 | P16070 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145412 | 0.84 | PNMT (0.52) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL130192 | 0.81 | — | — | |
| SCHEMBL34907 | 0.73 | — | — | |
| SCHEMBL16365929 | 0.72 | PNMT (0.42) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL24682 | 0.70 | — | — | |
| SCHEMBL8890 | 0.70 | TSHR (0.48) | MAOB | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.69 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.69 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.69 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL152117 | 0.68 | TSHR (0.46) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172667-A2 | SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-14 | — | — | WO | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-3953356-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | claimed |
| CN-113710672-A | hexahydro-1H-pyrazino [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2020207991-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-10280164-B2 | Pyrazolopyridone compounds and uses thereof | INCYTE CORPORATION (US) | 2019-05-07 | — | — | US | claimed |
| WO-2018049191-A1 | PYRAZOLOPYRIDONE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | claimed |
| US-20180072719-A1 | PYRAZOLOPYRIDONE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | claimed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999025709-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-27 | — | — | WO | claimed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | claimed |
| WO-1996002517-A1 | SUBSTITUTED ARYLSULFONAMIDES, THEIR PREPARATION AND USE AS THROMBIN-INHIBITING MEDICAMENTS | DR. KARL THOMAE GMBH (DE) | 1996-02-01 | — | — | WO | claimed |
| EP-0314852-B1 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA GEIGY AG (CH) | 1993-11-18 | — | — | EP | claimed |
| EP-0207563-B1 | A METHOD FOR CONTROLLING WEEDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-31 | — | — | EP | claimed |
| EP-0314852-A2 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA-GEIGY AG (CH) | 1989-05-10 | — | — | EP | claimed |
| EP-0289066-A1 | 1,5-Substituted 1H-imidazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-11-02 | — | — | EP | claimed |
| EP-0277384-A2 | 1H-imidazole-5-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-10 | — | — | EP | claimed |
| EP-0207563-A2 | A method for controlling weeds | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072719-A1 | PYRAZOLOPYRIDONE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | PNMT 3609/4885CD44 4858/4885MAOB 1952/4885 |
| US-10280164-B2 | Pyrazolopyridone compounds and uses thereof | PDXK, PCK1, PGK1 | PNMT 3609/4885CD44 4858/4885MAOB 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.